Subject:                                     StemTech Lab - NEWSLETTER -  #03 - 2010

 

   StemTech Labs              Newsletter  #03            2010

 

 

 If you prefer to view in your browser click here

 

 

 

 

We welcome you to our third edition of the Stem-Cell-Treatment-NOW.com newsletter on stem cells therapies. If you have any questions about our stem cell treatments, please direct inquiries to: MD@stemtechlab.com

If you like to read our previous newsletter click here

Our newsletters offer you information about the human umbilical stem cell treatments we offer. 

 

Contents

 

Articles:

 

Continuous improvement

One dose vs. a series

New Discount Pricing

New Clinic in Quito

STATUS OF STEM CELL TREATMENTS IN UNITED STATES

 

CONTINUOUS IMPROVEMENT

 

At StemTech Labs, we are constantly striving to improve our product, its effectiveness, and the patient’s experience.  Increasing the number of cells that we provide in each dose is one way that we have improved our produce.  Originally, based on other researcher’s experience, we had promised to provide at least 1.8 Million stem cells per dose (though we usually provided more than 10 million stem cells).  Newer research suggests that more cells are better for most adult treatments, and we are pleased that our laboratory procedures have allowed us to harvest a greater number of stem cells per donated cord.  So, we now guarantee at least 10 million stem cells per dose, with at least 1 million pluripotent mesencymal cells, for no additional price.  Please see below for our new price list, including discount prices for a series of treatments.

 

We have also made some improvement at reducing or eliminating a common side effect from stem cell treatment.  White blood cells are responsible for many of the effects of fever.  They release chemicals, called “cytokines,” that cause aches, increased temperature, chills, etc.  We may assume that such effects are the result of an infection, but actually, they are the result of the release of cytokines into the blood.  Cytokine release may be caused by infection, or other reasons.

 

Cytokines are also released by dead white blood cells, and they are released by live white blood cells even under storage at liquid nitrogen temperatures.  Since StemTech Labs umbilical cord blood stem cells are stored along with some white blood cells from the umbilical cord blood, each dose of stem cells has some cytokines in it, which can cause an uncomfortable reaction.  We have previously reduced the amounts of cytokines, which a patient receives along with a stem cell transfusion by repeatedly washing the storage fluid from the cells.  We have also found that by reducing the number of dead white blood cells in each dose of frozen cells, we can also reduce the side effects of the treatment.  We have made great improvements in our ratio of live to dead cells, so we can deliver more live stem cells without increasing your chance of having a fever-like reaction.  Please remember, when we tell you how many stem cells you will be receiving, this is the counted number of LIVE stem cells in your individual dose.

 

ONE DOSE VS. A SERIES

 

We have had almost 100% of our stem cell patients (or their families) report improvement following a stem cell treatment.  There are a few patients whose families report that they are improved, but the patients themselves report no change.  Still, most of our patients are not satisfied that their condition is completely resolved, and most desire additional treatments.   Similarly, other stem cell practitioners have found that one dose of stem cells, no matter what the number of stem cells, is not sufficient for many patients.  They have discovered that if there are acute (current or recent) medical problems present, like an infection, an injury or an inflammation, that the stem cells are attracted to these areas first.  That leaves only a few cells available to treat the chronic, on-going problems.  By giving a series of treatments, the acute problems are addressed by the stem cells on the first treatment, less acute ones on a second treatment, and chronic ones on the third treatment.  It may be ideal to wait one or two days between treatments, for the stem cells to find and begin work on the more acute problems, so that subsequent treatments are no longer attracted to these areas.  We offer a series of treatments in Quito, Ecuador for much less than most patients have been paying in the US for just one treatment, including travel and hotel expenses.  The cost of the cells is not included in these prices, but we do have new discount prices for a series.

 

For severe chronic problems, more than one series of treatments, separated by several months, may be recommended.   In Europe, stem cells are used for anti-aging purposes, and after an initial series, are administered once or twice a year.  A useful protocol would be: 3 treatments in 2 weeks, then once a month for another three, and then once every six months.  See our new prices for a series of treatments.

 

NEW DISCOUNT PRICING

 

In order to make it easier for you to order a series of treatments, and thus increase your chance of having the result that you desire, we have come up with discount treatments for a series of treatments.  Please be aware that each dose in the series contains the same guaranteed 10 Million live blood stem cells and 1 Million live mesenchymal stem cells.  Some practitioners have asked us to split the doses into three parts, and we may be able to provide this on a special-order basis.

 

For a single dose, with our new higher guaranteed live cell count, the price remains $5,000 US.  For a series of three doses of at least 11 Million cells each, the price is $7,500, or a 50% reduction in cost.  For a series of 5 treatments, the price is $12,000.  This is a discount of 52%.  A 10 treatment series, such as might be used for an anti-aging program, now costs only $22,500 US, or $2250 per treatment, for a savings of 55% over the cost of a single treatment.  Please note that these prices do not include shipping. To order click here

 

NEW CLINIC IN QUITO

 

We are proud to welcome Dr. Hernan Sotomayor, a trained surgeon now practicing alternative medicine, as our newest provider of stem cells.  Dr. Sotomayor (yes, that is the same name as the new justice of the supreme court) has just purchased a clinic in Quito, directly across the street from the Ministry of Culture and an easy walk to Plaza Foch, the heart of Quito’s night life, and is excited about providing stem cell treatments there.  The clinic is also an easy 2 block walk from the Swiss Hotel, where we will be housing our clients, 2 blocks from the Marriott, and about 4 blocks from the Holiday Inn-Quito.  The clinic has a consultation room, laboratory, several treatment rooms, and patient rooms for resting after a treatment.

 

                Dr. Sotomayor will be combining his skills in nutritional medicine and homeopathy with stem cell therapy, to increase the readiness of your body to receive the stem cells, and allow the stem cells to produce the result that you are looking for.  To schedule a treatment, or a series of treatments with Dr. Sotomayor, please order it here.

 

STATUS OF STEM CELL TREATMENTS IN UNITED STATES

 

The Food and Drug Administration continues to attempt to restrict the therapeutic use of natural, non-genetically modified stem cells in the United States.  Although Congress provided an exemption for the regulation of unmodified stem cells, the FDA has said that it would ignore that exemption, and treat umbilical cord stem cells as a drug.  We believe that this is illegal, but it makes physicians nervous about supplying stem cells from  us.  We have written to the FDA to ask for them to give a lawful reason why they have chosen to ignore the law and require unmodified stem cells to be treated as a drug or medical device, but they have twice refused to answer the letters that we sent to them by US Registered Mail.  This is undoubtedly because there is no legal reason for their decision.  Of course, that has never stopped them in the past—see this article about Dr. Stanislaw Burzynski: http://www.dwij.org/pathfinders/dan_haley/dan_2.html

 

StemTech Labs continues to negotiate with an independent Institutional Review Board to oversee a study of stem cell therapy in the United States.  Many of the physicians who have been administering stem cells feel that being a part of such a study would help to protect them against illegal activities from the FDA.

 

Some physicians have sought to bypass the FDA restriction on medial innovation by trying bone marrow stem cell transplants from a patient’s own body.  Unfortunately, the FDA forbids the culturing of these stem cells without them being regulated, investigated and marketed as a drug or medical device. There are thus not enough bone marrow stem cells in most cases to be useful for a medical condition.

 

Since the FDA has no jurisdiction over the practice of an individual physician, and since the FDA has no jurisdiction over treatments which a physician might prepare for use in his or her own practice, and since the FDA has no jurisdiction over any medical treatment not involved in interstate commerce, StemTech Labs has decided on a new approach to increase the availability of stem cell therapy in the United States.

 

We are looking for a number of physicians, or entrepreneurs who will work with a licensed physician, who would like to have their own stem cell laboratory in the United States, or elsewhere.  StemTech Labs will build out the laboratory, provide the equipment, supplies, protocols, and training, and will work with physicians to provide patients within their own state.   Please contact us if you would like to explore this option.

  

 

 

 Closing notes

 

 Thank you for reading this month's issue of StemTech Lab Monthly.


We'll see you again soon.

Editor: Leonardo Abello-Rode, Marketing Manager – StemTech Lab

Our Website: http://www.stemtechlab.com

Forum: http://www.stemtechlab.com/phpbb

Published monthly by:
StemTech Labs

Questions, Comments: editor@stemtechlab.com 

Medical question: MD@stemtechlab.com

Sales: sales@stemtechlab.com

USA: 1-305-515-8137

Not your subscription? Then signup to our FREE monthly newsletter

 

To unsubscribe just reply to this email with the word unsubscribe in the subject line

 

EMAIL DISCLAIMER - USA ONLY: The mesenchymal and umbilical cord blood stem cells used in this study are human cells, tissues, or cellular and tissue-based products (HCT/Ps) as defined in 21 CFR § 1271.3(d). Under 21 CFR Part 1271, HCT/Ps are not subject to licensure or IND requirements if certain criteria are met (21 CFR § 1271.10). These requirements include autologous use (use by the cell donor), or if used for other patients, the HCT/Ps must be “not more than minimally manipulated” and labeled for use for “homologous use only”. They may also not be used for a purpose requiring their “metabolic” activity. StemLab S.A. mesenchymal and umbilical cord stem cells shipped to the United States of America have not been “more than minimally manipulated”. StemLab S.A. labels and intends its cells which are used within the United States of America only for homologous and non-metabolic purposes. StemLab S.A. does not interfere with the practice of medicine by individual physicians who use StemLab products, and who may do so according to their own medical training and informed choice.

 

The information contained in this message may be privileged and confidential, protected from disclosure, and/or intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any disclosure, distribution, copying or other dissemination of this communication is strictly prohibited. If you received this communication in error, please immediately reply to the sender, delete the message and destroy all copies of it. All rights reserved.  Publishing this information or using it in any matter other than it is intended purposed is strictly prohibited. Thank You

 

"La información que contiene esta comunicación es de naturaleza confidencial y puede que contenga información privilegiada. Dicha información es para el solo uso del destinatario. Si usted no es la persona a quien se le dirige esta comunicación o la persona que puede hacerle llegar esta comunicación a su destinatario, deseamos hacerle saber que el retener, diseminar, divulgar, distribuir, copiar o cualquier otro uso que se le di a esta comunicación y a la información que la misma contiene, esta estrictamente prohibida. Si usted ha recibido esta comunicación por equivocación, notifíquennoslo.  Todo derecho reservado.  Gracias